doxylamine indications/contra

Stem definitionDrug idCAS RN
962 469-21-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • doxylamine
  • (+/-)-Doxylamine
  • doxylamine succinate
Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.
  • Molecular weight: 270.38
  • Formula: C17H22N2O
  • CLOGP: 2.35
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 25.36
  • ALOGS: -2.70
  • ROTB: 6

Drug dosage:

DoseUnitRoute
25 mg O

Approvals:

DateAgencyCompanyOrphan
April 7, 1948 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 1089.98 104.74 220 602 18110 3366927
Toxicity to various agents 1089.58 104.74 259 563 46795 3338242
Completed suicide 836.27 104.74 195 627 30919 3354118
Intentional product misuse 220.24 104.74 57 765 12644 3372393
Intentional overdose 163.89 104.74 47 775 15178 3369859
Overdose 149.39 104.74 53 769 33925 3351112
Cardio-respiratory arrest 145.46 104.74 43 779 15397 3369640
Cardiac arrest 140.75 104.74 48 774 27271 3357766
Respiratory arrest 139.87 104.74 39 783 11329 3373708
Death 137.54 104.74 78 744 152246 3232791

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC R06AA09 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Aminoalkyl ethers
ATC R06AA59 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Aminoalkyl ethers
CHEBI has role CHEBI:37956 histamine antagonist
CHEBI has role CHEBI:48873 cholinergic antagonist
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:37955 H1-receptor antagonist
CHEBI has role CHEBI:51177 antitussive
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:50857 anti-allergic agent
MeSH PA D000932 Antiemetics
MeSH PA D001337 Autonomic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175750 Antihistamine
FDA MoA N0000000207 Histamine Receptor Antagonists

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Urticaria indication 126485001
Influenza-like symptoms indication 315642008
Seasonal allergic rhinitis indication 367498001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Ocular hypertension contraindication 4210003 DOID:9282
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Ventricular tachycardia contraindication 25569003
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Hepatic failure contraindication 59927004
Arterial thrombosis contraindication 65198009
Poisoning by acetaminophen contraindication 70273001
Arteriosclerotic vascular disease contraindication 72092001 DOID:2349
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009 DOID:2883
Retention of urine contraindication 267064002
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Hypertensive urgency contraindication 443482000
Morning sickness off-label use 51885006

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.83 Basic
pKa2 4.29 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG DICLEGIS DUCHESNAY N021876 April 8, 2013 RX TABLET, DELAYED RELEASE ORAL 6340695 June 21, 2021 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
20MG BONJESTA DUCHESNAY N209661 Nov. 7, 2016 RX TABLET, EXTENDED RELEASE ORAL 9089489 Feb. 18, 2033 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
20MG BONJESTA DUCHESNAY N209661 Nov. 7, 2016 RX TABLET, EXTENDED RELEASE ORAL 9375404 Feb. 18, 2033 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
20MG BONJESTA DUCHESNAY N209661 Nov. 7, 2016 RX TABLET, EXTENDED RELEASE ORAL 9526703 Feb. 18, 2033 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST CHEMBL CHEMBL

External reference:

scroll-->
IDSource
DB00366 DRUGBANK_ID
4019738 VUID
N0000147830 NUI
C0013092 UMLSCUI
7171 IUPHAR_LIGAND_ID
D02327 KEGG_DRUG
CHEMBL1004 ChEMBL_ID
3162 PUBCHEM_CID
3642 RXNORM
44068004 SNOMEDCT_US
412380009 SNOMEDCT_US
d03154 MMSL
4019738 VANDF
N0000147830 NDFRT
N0000008027 NDFRT
004789 NDDF
95QB77JKPL UNII
1782 INN_ID
CHEBI:51380 CHEBI
CHEMBL1200392 ChEMBL_ID
C035385 MESH_SUPPLEMENTAL_RECORD_UI
D004319 MESH_DESCRIPTOR_UI
562-10-7 SECONDARY_CAS_RN

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Robitussin Maximum Strength Nighttime Cough DM HUMAN OTC DRUG LABEL 2 0031-8717 LIQUID 12.50 mg ORAL OTC MONOGRAPH FINAL 9 sections
Robitussin Maximum Strength Nighttime Cough DM HUMAN OTC DRUG LABEL 2 0031-8718 SOLUTION 12.50 mg ORAL OTC MONOGRAPH FINAL 9 sections
ROBITUSSIN PEAK COLD NIGHTTIME COLD PLUS FLU HUMAN OTC DRUG LABEL 3 0031-8722 CAPSULE, LIQUID FILLED 6.25 mg ORAL OTC MONOGRAPH FINAL 9 sections
Good Sense Severe NightTime HUMAN OTC DRUG LABEL 4 0113-0019 SOLUTION 12.50 mg ORAL OTC monograph final 16 sections
good sense night time HUMAN OTC DRUG LABEL 3 0113-0056 CAPSULE, GELATIN COATED 6.25 mg ORAL OTC monograph final 8 sections
good sense DayTime Night Time HUMAN OTC DRUG LABEL 6 0113-0090 KIT 6.25 mg None OTC monograph final 9 sections
good sense night time HUMAN OTC DRUG LABEL 3 0113-0335 SOLUTION 12.50 mg ORAL OTC monograph final 16 sections
Good Sense Severe Sinus Congestion HUMAN OTC DRUG LABEL 4 0113-0345 CAPSULE, LIQUID FILLED 6.25 mg ORAL OTC monograph final 15 sections
Good sense sleep aid HUMAN OTC DRUG LABEL 1 0113-0441 TABLET 25 mg ORAL ANDA 9 sections
good sense nighttime HUMAN OTC DRUG LABEL 3 0113-0459 SOLUTION 12.50 mg ORAL OTC monograph final 9 sections
Good Sense NightTime DayTime Cold and Flu HUMAN OTC DRUG LABEL 6 0113-0567 KIT 12.50 mg None OTC monograph final 17 sections
good sense cough and sore throat HUMAN OTC DRUG LABEL 3 0113-0666 LIQUID 6.25 mg ORAL OTC monograph final 9 sections
Good Sense Nighttime Cough HUMAN OTC DRUG LABEL 2 0113-0668 SOLUTION 12.50 mg ORAL OTC monograph final 9 sections
Basic Care Nighttime HUMAN OTC DRUG LABEL 3 0113-7459 SOLUTION 12.50 mg ORAL OTC monograph final 8 sections
Alka-Seltzer Plus Night Cold HUMAN OTC DRUG LABEL 4 0280-0052 TABLET, EFFERVESCENT 6.25 mg ORAL OTC monograph final 9 sections
Alka-Seltzer Plus Severe Cold and Cough Night HUMAN OTC DRUG LABEL 3 0280-0056 LIQUID 12.50 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus Severe Cough Mucus and Congestion Day and Night HUMAN OTC DRUG LABEL 8 0280-0506 KIT 6.25 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus Night Severe Cold and Flu HUMAN OTC DRUG LABEL 4 0280-0922 POWDER, FOR SOLUTION 12.50 mg ORAL OTC monograph final 9 sections
Alka-Seltzer Plus Day and Night Severe Cold and Flu HUMAN OTC DRUG LABEL 8 0280-0924 KIT 12.50 mg None OTC monograph final 9 sections
Alka-Seltzer Plus HUMAN OTC DRUG LABEL 7 0280-1122 KIT 6.25 mg None OTC monograph not final 9 sections
Alka-Seltzer Plus HUMAN OTC DRUG LABEL 4 0280-1124 CAPSULE, LIQUID FILLED 6.25 mg ORAL OTC monograph final 9 sections
Alka-Seltzer Plus HUMAN OTC DRUG LABEL 4 0280-1125 CAPSULE, LIQUID FILLED 6.25 mg ORAL OTC monograph final 9 sections
Alka-Seltzer Plus HUMAN OTC DRUG LABEL 14 0280-1126 KIT 6.25 mg None OTC monograph final 9 sections
Alka-Seltzer Plus HUMAN OTC DRUG LABEL 14 0280-1126 KIT 6.25 mg None OTC monograph final 9 sections
Alka-Seltzer Plus Multi-Smptom Cold and Flu Night HUMAN OTC DRUG LABEL 4 0280-1137 CAPSULE, LIQUID FILLED 6.25 mg ORAL OTC monograph not final 17 sections
Alka-Seltzer Plus Multi-Symptom Cold and Flu Day and Night HUMAN OTC DRUG LABEL 7 0280-1138 KIT 6.25 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus HUMAN OTC DRUG LABEL 7 0280-1140 KIT 6.25 mg None OTC monograph not final 15 sections
Alka-Seltzer Plus Severe Sinus Congestion and Cough Liquid Gels Night HUMAN OTC DRUG LABEL 4 0280-1222 CAPSULE, LIQUID FILLED 6.25 mg ORAL OTC monograph final 16 sections
Alka-Seltzer Plus HUMAN OTC DRUG LABEL 4 0280-1430 TABLET, EFFERVESCENT 6.25 mg ORAL OTC MONOGRAPH FINAL 9 sections
Alka-Seltzer Plus Multi-Symptom Cold Day and Night HUMAN OTC DRUG LABEL 7 0280-1540 KIT 6.25 mg ORAL OTC monograph final 16 sections